EUVIMEDEUVIMED entdecken
Crossref

Overexpressing Bcl-2 enhances murine chimeric antigen receptor T cell therapy against solid tumor

Xiaoyan Wang, Guodong Liu, Xianggang Shi, Yuxing Wang, Bo Jiang, Wei Liu, Anran Dai, Xiangzhi Zhang, Feng Yu

Human Cell · 2024

DOI: 10.1007/s13577-024-01066-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Cell, 2024. Verfasst von Xiaoyan Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Suqian First People's Hospital, Suqian, 223800, Jiangsu, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-bcl-2, Receptors, Chimeric Antigen, ErbB Receptors, Disease Models, Animal. Die Arbeit nennt 21 Literaturangaben. Gefördert von: Suqian Sci & Tech Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T (CART) cell therapy has demonstrated promising potential in the treatment of hematologic malignancies. However, its application to solid tumors is limited due to the restrictive nature of the tumor microenvironment, resulting in functional failure and poor persistence of CART cells. Overexpression of Bcl-2 in human CART cells (hCART) has been found to significantly enhance their anti-apoptotic effects both in vitro and in vivo. Nevertheless, the evaluation of hCART cells in preclinical studies has predominantly relied on immunodeficient mice xenograft tumor models, making it challenging to assess the impact of hCART cells on normal tissues and the immune system. We established a murine CART (mCART) that overexpresses Bcl-2 and targets the epidermal growth factor receptor variant III (EGFRvIII), named EGFRvIII·mCART-Bcl2. It demonstrated superior proliferation, cytotoxicity, and anti-apoptotic capabilities in vitro. In an immunocompetent mouse model of abdominal metastasis of colorectal cancer, EGFRvIII·mCART-Bcl2 exhibited improved survival of CART in the abdomen, increased tumor clearance, and significantly prolonged overall mouse survival. In summary, our study provides evidence that the introduction of Bcl-2 into mCART cells can enhance their therapeutic efficacy against solid tumors while ensuring safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-bcl-2Receptors, Chimeric AntigenErbB ReceptorsDisease Models, AnimalAnimalsMiceHumansImmunotherapy, AdoptiveGene ExpressionApoptosisCell ProliferationColorectal NeoplasmsCell- and Tissue-Based TherapyTumor MicroenvironmentCell Line, Tumor

Stichwörter der Autor:innen

Bcl-2Murine CARTSolid tumor

Substanzen

Proto-Oncogene Proteins c-bcl-2Receptors, Chimeric AntigenErbB Receptorsepidermal growth factor receptor VIII

Autor:innen und Institutionen

  • Department of Gastroenterology, Suqian First People's Hospital, Suqian, 223800, Jiangsu, China.
  • Department of General Surgery, Suqian First People's Hospital, Suqian, 223800, Jiangsu, China.
  • School of Life Sciences, Jiangsu University, Zhenjiang, 212013, China. 1974253281@qq.com.
  • School of Life Sciences, Jiangsu University, Zhenjiang, 212013, China.
  • School of Life Sciences, Jiangsu University, Zhenjiang, 212013, China. yufeng@ujs.edu.cn.

Förderung

  • Suqian Sci & Tech Program

Zitieren

APA

Wang, X., Liu, G., Shi, X., Wang, Y., Jiang, B., Liu, W., Dai, A., Zhang, X., & Yu, F. (2024). Overexpressing Bcl-2 enhances murine chimeric antigen receptor T cell therapy against solid tumor. Human Cell. https://doi.org/10.1007/s13577-024-01066-x

Vancouver

Wang X, Liu G, Shi X, Wang Y, Jiang B, Liu W, et al. Overexpressing Bcl-2 enhances murine chimeric antigen receptor T cell therapy against solid tumor. Human Cell. 2024. doi:10.1007/s13577-024-01066-x

BibTeX
@article{Wang2024,
  author = {Wang, Xiaoyan and Liu, Guodong and Shi, Xianggang and Wang, Yuxing and Jiang, Bo and Liu, Wei and Dai, Anran and Zhang, Xiangzhi and Yu, Feng},
  title = {Overexpressing Bcl-2 enhances murine chimeric antigen receptor T cell therapy against solid tumor},
  journal = {Human Cell},
  year = {2024},
  doi = {10.1007/s13577-024-01066-x}
}
Kostenlos starten →